Table 2.

Progression-free survival of SMM and symptoms at time of progression stratified by FLCr ≥100 or <100 and BMPC percentage ≥60 or <60

	All patients	FLCR <100	FLCR ≥100	P	BMPC <60	BMPC ≥60	P
Patients, n	273	156	27		251	22
Progressed, n (%)	123 (45)	56 (36)	15 (56)		107 (43)	16 (73)
Progression event, n (%)*
Hypercalcemia	4 (3)	2 (4)	0 (0)	1.0000	4 (4)	0 (0)	1.0000
Renal insufficiency	11 (9)	2 (4)	3 (20)	.0599	11 (10)	0 (0)	.3560
Anemia	62 (50)	33 (59)	10 (67)	.7677	52 (49)	10 (63)	.2996
Bone disease	64 (52)	25 (45)	8 (53)	.5742	55 (51)	9 (56)	.7173

^*Total number of progression events exceeds the number of patients who progressed as patients may have progressed by multiple events.